Following the commercialization of its core product Vipenatide, PegBio is adding new product forms and overseas development pathways for its next-generation metabolic innovation pipeline.
It has been learned that the Hong Kong-listed company PegBio Co-B (02565) recently signed a memorandum of understanding with US-listed Rani Therapeutics (RANI.US). The two parties intend to collaborate on the oral delivery and preclinical development of several innovative candidate assets from PegBio's obesity and metabolic disease pipeline using Rani's proprietary RaniPill® platform, and explore potential cooperation for the research, production, and commercialization of related products in markets outside of China. According to information disclosed by Rani, the plan is to screen candidate projects from PegBio's multiple metabolic innovation assets that are suitable for oral delivery, with the goal of advancing the most promising among them into clinical development.
A Step Beyond a Single Oral Project
From a capital markets perspective, the significance of this collaboration extends beyond merely adding an oral delivery project. PegBio has already established a tiered pipeline comprising the commercialized product Vipenatide, the ultra-long-acting platform CR059, and next-generation obesity candidate assets represented by APGP6. The addition of the RaniPill® has the potential to simultaneously introduce a new variable—oral delivery—to metabolic assets at different stages and with different mechanisms. This implies that PegBio's valuation rationale may extend from a single commercial product to encompass three additional dimensions: next-generation pipeline, formulation innovation, and global business development.
Vipenatide: Validating PegBio's Capability to Address GLP-1 Challenges
PegBio's self-developed once-weekly GLP-1 receptor agonist, Vipenatide, was approved for market launch in November 2025, marking the company's official transition from a research-focused biotech to a commercial-stage entity. Unlike some GLP-1 products that require gradual dose titration from a low starting point, Vipenatide can be initiated at the therapeutic dose, eliminating the need for prolonged dose escalation. It also features rapid onset, stable glucose-lowering effects, and sustained efficacy. In long-term studies, Vipenatide demonstrated consistently stable blood glucose control without significant efficacy rebound. Its low incidence of gastrointestinal adverse reactions also gives it differentiated advantages in terms of safety, tolerability, and long-term treatment adherence.
The significance of Vipenatide is not limited to PegBio having a GLP-1 product on the market. It validates the company's capability in molecular design, clinical development, and product translation, specifically addressing core clinical challenges such as onset speed, glycemic stability, long-term efficacy, and safety/tolerability. On this foundation, oral delivery is not a means to compensate for the shortcomings of an ordinary molecule; rather, it is about removing the injection barrier for a product that already possesses differentiated clinical value. If the related technology can be realized, a GLP-1 product characterized by rapid onset, stability, durability, and excellent tolerability could potentially reach more patients with low acceptance of injections and enter broader scenarios for early treatment and long-term chronic disease management.
CR059: From Monthly and Quarterly Dosing to Exploring Low-Frequency Oral Delivery
If Vipenatide represents the end of PegBio's journey that has already undergone commercial validation, CR059 represents its next-generation ultra-long-acting technology platform. CR059 is a circular RNA-encoded long-acting GLP-1 receptor agonist platform. Its core concept is not the direct injection of a peptide, but rather the sustained in vivo expression of a therapeutic protein via circular RNA, exploring the possibility of monthly or even quarterly dosing.
Transitioning from weekly to monthly administration means the annual dosing frequency could drop from approximately 52 times to about 12 times. If quarterly dosing is further achieved, it might require only about 4 doses per year. The new possibility introduced by the RaniPill® is the attempt to combine this ultra-long-acting in vivo expression capability with oral delivery. If the related technology is ultimately validated, future oral GLP-1 products may no longer be confined to daily dosing. Instead, they could form a previously undefined new product category: a capsule that, once taken orally, provides therapeutic effects lasting for several weeks or even longer. This would simultaneously change both the mode and frequency of administration.
For long-term management of diabetes, obesity, and other metabolic diseases, if the three attributes of low frequency, long duration, and oral administration can be realized in a single product, its clinical value and commercial potential could far exceed that of traditional formulation improvements. Of course, the combination of CR059 with an oral platform is still in the conceptual and early evaluation stage. Subsequent validation regarding formulation compatibility, pharmacokinetics, pharmacodynamics, and safety is still required. Precisely because its goal is not simply turning a weekly injectable into an oral formulation, but rather exploring low-frequency oral biologics, its potential product value and global cooperation prospects are even more noteworthy.
APGP6: Adding Oral Delivery to "Weight Loss and Muscle Gain"
In the next-generation obesity treatment field, PegBio has also positioned APGP6, which holds value for weight loss while preserving, and potentially even increasing, muscle mass. Historically, competition in obesity drugs has primarily revolved around the magnitude of weight loss. However, as GLP-1 and multi-target drugs continue to set new records for weight reduction, market focus is gradually shifting from "how much weight is lost" to "what exactly is being lost."
For obese patients, weight loss does not entirely equate to health benefits. If weight loss is accompanied by excessive loss of lean body mass and muscle, it can affect basal metabolism, physical strength, quality of life, and long-term weight maintenance. What APGP6 seeks to address is precisely the core question for next-generation obesity drugs: achieving significant weight loss while more effectively reducing adipose tissue and concurrently preserving lean body mass and improving muscle-related metrics. In other words, APGP6 aims not merely to lower the number on the scale, but to enhance the quality of weight loss.
If a candidate drug capable of achieving fat loss, muscle preservation, and even showing potential for muscle gain is further adapted for oral delivery in the future, its product potential would be magnified once again. It could simultaneously cover two main themes in next-generation obesity drug competition: one is higher-quality weight loss, meaning fat loss rather than simple weight reduction; the other is more convenient administration, transitioning from injection to oral. If significant weight loss, muscle protection, and oral convenience can be achieved in a single product, APGP6 could establish a differentiated positioning distinct from traditional GLP-1s and products solely pursuing weight loss magnitude.
It is important to note that the current disclosure is about establishing a framework for oral delivery collaboration around multiple metabolic candidate assets; it does not mean APGP6 has been confirmed for specific development. However, considering PegBio's existing pipeline structure, assets like APGP6, which focus on weight loss and muscle preservation, represent one of the most promising potential application directions for a future oral platform.
Oral Delivery: Adding an Asset Portfolio, Not Just a Formulation
Traditional business development for innovative drugs typically revolves around a product with a defined formulation and development pathway, selling the development and commercialization rights for a specific region. The capital markets value of oral delivery lies in its potential to redefine how an asset can be split and transacted. A molecule originally developed as an injectable, after validation with an oral platform, could further give rise to: two product forms (injectable and oral); relatively independent formulation patents and clinical development pathways; differentiated product positioning for different patients and treatment stages; and various cooperation models divided by formulation, region, indication, and development stage.
This means a single innovative molecule could transform from a single licensing asset into a portfolio of assets with independent development and transaction potential. For PegBio, if Vipenatide, CR059, APGP6, and other multi-target candidate assets each gain an oral development pathway, the value would not merely be having several oral versions. It could further lead to various transaction structures involving formulation rights, regional rights, co-development, and commercialization partnerships. Therefore, oral delivery not only enhances patient convenience but also increases the flexibility of asset operation and potential business development options.
Rani's Contribution: An International Platform Partner Already in Clinical Stage
The technical and capital markets background of the partner is another important factor worthy of attention in this collaboration. Rani Therapeutics is a US-listed, clinical-stage biopharmaceutical company that has long focused on the oral delivery of biologics and drugs. Its core RaniPill® platform is designed to deliver biologics, which traditionally require subcutaneous injection or intravenous infusion, via an oral capsule. Rani has conducted multiple preclinical and clinical studies around this platform. In the obesity field, Rani is advancing the oral GLP-1/GLP-2 dual receptor agonist RT-114, which has entered Phase I clinical trials. The company has also completed preclinical studies on several obesity candidate drugs, including semaglutide.
Therefore, what PegBio is accessing is not a technology stuck at the laboratory concept stage, but rather an oral biologic platform that has already entered clinical development, is connected to the US capital markets, and possesses a foundation for international cooperation. PegBio contributes a metabolic innovation pipeline ranging from an approved GLP-1 product and an ultra-long-acting platform to weight-loss/muscle-preservation candidate assets. Rani contributes the delivery technology to overcome the injection limitation for these assets and an overseas development platform. The logic of their collaboration is not merely a technology purchase; it is an attempt to create a new set of assets for the global market at the intersection of innovative molecules and an oral platform.
From Commercial Biotech to Global Asset Operator
Following the approval and launch of Vipenatide, PegBio has completed the transition from a research-focused biotech to a commercial-stage biopharmaceutical company. But Vipenatide is not the end of the company's story. CR059 represents the direction of ultra-long-acting therapy on a monthly or even quarterly basis. APGP6 represents the next-generation obesity treatment logic shifting from weight loss magnitude to weight loss quality. Other multi-target assets further cover blood sugar control, weight loss, body fat reduction, and comprehensive metabolic benefits.
The addition of the RaniPill® has the potential to add two dimensions—oral delivery and international development—to these assets with different mechanisms and at different stages. This collaboration is directed at markets outside China from the outset. If related projects yield positive results, the two parties could further explore cooperation in R&D, production, and commercialization. This suggests that PegBio's internationalization path is extending beyond traditional product licensing towards technology co-creation, formulation development, joint development, and global asset incubation.
From a capital markets perspective, PegBio's future value may no longer depend solely on the commercial performance of Vipenatide. It will also include whether CR059, APGP6, and other next-generation assets can form new growth curves through oral delivery, overseas development, and potential BD transactions. Currently, the parties have only signed a memorandum of understanding. Uncertainty remains regarding whether specific candidate projects will proceed to substantive development, whether technical validation will yield positive results, and whether the parties can reach formal R&D or commercialization agreements. However, the signal released by this collaboration is relatively clear: Vipenatide addresses product issues of rapid onset, stable control, durable efficacy, and safety/tolerability for GLP-1 drugs. CR059 attempts to address the issue of dosing frequency in chronic treatment. APGP6 targets the issues of muscle loss and weight loss quality during weight reduction. And the RaniPill® seeks to address the long-standing reliance on injections for these innovative biologics.
When these four dimensions are integrated into a single pipeline, what PegBio is attempting to build may no longer be just a few independent metabolic innovation drugs. It could be a next-generation metabolic asset platform capable of continuously combining around efficacy, weight loss quality, dosing frequency, formulation, and global cooperation.
Comments